CE-326597

CE‑326597 is a small molecule drug developed by Pfizer as a potent and selective agonist of the cholecystokinin A receptor (CCKAR). It was investigated primarily for the treatment of obesity and type 2 diabetes mellitus. The drug was designed to be orally active and gut-selective with low systemic exposure due to poor absorption in the intestinal wall. Its mechanism involves activation of CCKAR, which mediates satiety signaling and nutrient homeostasis by modulating feeding behavior through G protein-coupled pathways that activate phosphatidylinositol-calcium second messenger systems. Despite reaching Phase II clinical trials for both obesity and type 2 diabetes mellitus, development was discontinued due to insufficient efficacy[3][4][8].

Other names

N-benzyl-2-(4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-(1,2,4)triazolo(4,3-a)(1,5)benzodiazepin-6-yl)-N-isopropylacetamideUNII 1FGZ6L9SF2UNII1FGZ6L9SF2UNII-1FGZ6L9SF21FGZ6L9SF2CE 326597CE326597CE-326597